Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13

• Published in: Blood Vol. 113; no. 5; pp. 1002 - 1005
• Main Authors: Fehniger, Todd A., Byrd, John C., Marcucci, Guido, Abboud, Camille N., Kefauver, Cheryl, Payton, Jacqueline E., Vij, Ravi, Blum, William
• Format: Journal Article
• Language: English
• Published: Washington, DC Elsevier Inc 29.01.2009; Americain Society of Hematology; American Society of Hematology
• Series: Clinical Trials and Observations
• Subjects: Aged; Antineoplastic Agents - administration & dosage; Biological and medical sciences; Chromosomes, Human, Pair 13 - genetics; Clinical Trials and Observations; Hematologic and hematopoietic diseases; Humans; Lenalidomide; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - genetics; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Remission Induction - methods; Thalidomide - administration & dosage; Thalidomide - analogs & derivatives; Trisomy - genetics; Antineoplastic agent; Human; Acute myelogenous leukemia; Hematology; Lenalidomide; Patau syndrome; Remission; Malignant hemopathy; Cancer
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood-2008-04-152678

Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q− chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 and NCT00546897.